MRI of Glutamate Modulation in-vivo

K. Cai1, M. Haris1, A. Singh1, F. Kogan1, W. R. Witschey1, P. Waghray1, J. H. Greenberg1, H. Harirhan1, J. A. Detre2, and R. Reddy1

1CMROI, Department of Radiology, University of Pennsylvania, Philadelphia, PA, United States, 2Department of Neurology, University of Pennsylvania, Philadelphia, PA, United States

Introduction:
Glutamate (Glu) is the major neurotransmitter for fast excitatory synaptic transmission, and is likely involved in all signal processing functions of the central nervous system (CNS), and are altered in many CNS diseases. Because of its critical role in neurological and psychiatric disorders, Glu may also serve as potential surrogate marker for diagnosis, treatment, and evaluation of therapeutic efficacy. Traditional magnetic resonance spectroscopy (MRS) for detection of Glu requires long acquisition times (8-10 min) and generally provide poor spatial and temporal resolution. Given these shortcomings, there is a clear need for developing improved methods for imaging of these neurotransmitters, preferably with high spatial and temporal resolution using noninvasive and nonradioactive means. This study demonstrates that Glu exhibits a pH-dependent chemical exchange saturation transfer (CEST) effect (GluCEST) between its -NH2 group and bulk water in a concentration dependent manner. Glu modulation via intravenous injection in a rat brain tumor model resulted in clear elevation of GluCEST as well as a comparable increase in the signal of -CH2 resonance of Glu measured by single voxel spectroscopy (SVS).

Methods:
In-vitro experiments were performed at 37°C and on 7 T Siemens whole body MRI scanner using a single channel circular polarized (CP) transmit-receive head coil. Glu Phantoms (at different pH and concentrations) in PBS were imaged using a custom-built CEST sequence with frequency-selective and Hanning-windowed saturation pulses (peak $B_1=250$Hz for 2s) followed by a segmented RF spoiled gradient echo (GRE) readout. Tumor-bearing rats with compromised blood-brain barrier were imaged at a Varian 9.4T MR scanner with a continuous-wave rectangular saturation pulse (peak $B_1=250$Hz for 1s). After collecting the baseline CEST map and SVS spectra, the animals were slowly injected with 2.5ml, 100mM Glu solution intravenously. CEST and SVS data were gathered periodically for about 2 hours post injection. GluCEST maps were calculated by normalizing the difference of -3ppm and +3ppm images over 3ppm image. GluCEST contrast maps were corrected for $B_0$ and $B_1$ inhomogeneities.

Results:
CEST Z-spectra of 10mM Glu at varying pH are shown in Figure 1A. At lower pH (pH 4.0), the CEST peak of Glu is sharper and centered at 3ppm. At physiological intracellular pH 7.0, Glu showed a broad CEST effect. CEST contrast from Glu at different concentrations and pH 7.0 is shown in Figure 1B. The GluCEST effect is linearly proportional to the Glu concentration in the measured range. This demonstrates that the GluCEST effect can serve as an index of Glu concentration. Glu modulation of a tumor-bearing rat brain was performed by injecting Glu solution intravenously. Figure 2B and C show GluCEST maps obtained before and 2 hour post Glu injection. GluCEST contrast increases, especially in the tumor region, due to the compromised blood-brain barrier. A comparable elevation in the amplitude of Glu –CH2 resonance was seen from corresponding SVS (Figure 2D.). Numerical simulations of Bloch–McConnell equations of Glu-NH2 Chemical Exchange also show that the exchange rate of Glu –NH2 protons are in the slow to intermediate regime at field strength of 7Tesla.

Conclusion:
CEST effect of Glu has been characterized and its modulation in-vivo has been demonstrated by injection of Glu intravenously. The feasibility of quantifying Glu map in human brain and the potential overlap from other brain metabolites are under study. This method provides noninvasive, nonradioactive and high spatial and temporal resolution imaging of Glu modulations in-vivo. Future studies using this approach may provide new insights into Glu function and demonstrate its potential as a biomarker for the diagnosis and treatment of CNS disorders.

Acknowledgement:
This work was performed at an NCRR supported Biomedical Technology and Research Center (P41 RR02305).